Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants

Inclusion Criteria:

• Male or female, of any race, between 18 and 65 years of age

• In good health, as determined by no clinically significant findings from medicalhistory,12- lead ECG and vital signs measurements, physical examination and clinicallaboratory evaluations

• Body mass index between 18.0 and 32.0kg/m2, inclusive

Exclusion Criteria:

• Significant history or clinical manifestation of any metabolic, allergic,dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, asdetermined by the investigator or designee.

• Evidence of any infections (bacterial, viral, fungal, parasitic) within 4 weeksprior to the first dose of study drug, as determined by the investigator (ordesignee).

• History of malignancy, except for appropriately treated carcinoma in situ of thecervix or nonmelanoma skin carcinoma not requiring ongoing systemic treatment.

• History of stomach or intestinal surgery or resection that would potentially alterabsorption and/or excretion of orally administered drugs (uncomplicated appendectomyand hernia repair are allowed).

• Participants who have acute gastrointestinal symptoms at the time of screening andor/admission (eg, nausea, vomiting, diarrhea, or heartburn).